FOR IMMEDIATE ATTENTION
- -----------------------


Deborah Carty                                Clint Cantwell
NexMed, Inc.                                 Rubenstein Investor Relations, Inc.
(609) 208-9688, ext: 159                     212-843-8001
dcarty@nexmed.com                            ccantwell@rubensteinir.com


           NEXMED ANNOUNCES POSITIVE PHASE 3 RESULTS FOR ALPROX-TD(R)

          -COMPLETE DATA TO BE PRESENTED DURING ICESD LATER THIS MONTH-

Robbinsville, NJ, June 12, 2003 -- NexMed, Inc. (Nasdaq: NEXM), a developer of
transdermal treatments based on its NexACT(R)drug delivery technology, today
announced positive top-line results from its two pivotal Phase 3 studies of
Alprox-TD(R) cream treatment for erectile dysfunction ("ED"). The clinical data
indicated that the three dose levels of Alprox-TD(R) tested were effective over
placebo in each study and in the combined analysis of the two studies. All doses
showed a highly significant (p= 0.001 or p< 0.001) increase in Erectile Function
Domain scores using the International Index of Erectile Function (IIEF), the
gold standard for measuring efficacy in ED products. The side effects reported
were mostly mild to moderate, localized and transient. The overall
discontinuance rate due to side effects was less than 4%.

Dr. Wayne Hellstrom, Chief of Section of Andrology and Male Infertility at
Tulane University School of Medicine, will present the complete set of data from
the two Alprox-TD(R) pivotal Phase 3 studies at the 2nd International
Consultation on Erectile and Sexual Dysfunction, which is co-sponsored by the
World Health Organization, and will take place from June 28 to July 1, 2003 in
Paris, France.

Over 1,700 patients with mild to severe ED were enrolled in the two pivotal
Phase 3 studies. The studies, conducted at 85 US research clinics, were
randomized, double-blind, placebo-controlled, and were designed to confirm the
efficacy and safety of Alprox-TD(R) in patients with mild to severe ED.
Alprox-TD(R) incorporates alprostadil with NexMed's patented NexACT(R)
technology. The studies included patients who had not previously taken ED
medications as well as patients who had little or no success with the currently
approved oral medications for ED. Many of these patients also had diabetes,
prostatectomies, hypertension and other serious medical conditions.

NexMed also announced that it is sending a notice for the release of escrowed
funds to the escrow agent and the investors who participated in its April 21,
2003 private placement. At closing, $4 million of the proceeds were placed in
escrow to fund any potential redemption by the purchasers to which they may be
entitled if the results from NexMed's two pivotal Phase 3 studies for
Alprox-TD(R) were determined to be unsatisfactory.

Dr. Y. Joseph Mo, President and C.E.O., commented, "We are delighted by these
results. We have worked long and hard to achieve this milestone. It is the most
significant event in NexMed's history. We look forward to sharing these results
with potential marketing partners for Alprox-TD(R)."

Dr. James Yeager, Senior Vice-President for Scientific Affairs, said, "We
continue to review the data for additional analysis of the safety and efficacy
of our product in different populations including those patients who cannot take
or have failed the marketed oral medications, and/or who have medical conditions
such as hypertension, diabetes and/or cardiovascular complications." Dr. Yeager
added, "We look forward to presenting these subset analyses to our colleagues at
the Paris conference."






About NexMed, Inc.
- ------------------

NexMed, Inc. is an emerging pharmaceutical and medical technology company, with
a product development pipeline of innovative treatments based on the NexACT(R)
transdermal delivery technology. Its lead NexACT(R) product under development is
the Alprox-TD(R) cream treatment for erectile dysfunction. The Company is also
working with various pharmaceutical companies to explore the incorporation of
NexACT(R) into their existing drugs as a means of developing new
patient-friendly transdermal products and extending patent lifespans and brand
equity.

Statements under the Private Securities Litigation Reform Act: with the
exception of the historical information contained in this release, the matters
described herein contain forward-looking statements that involve risk and
uncertainties that may individually or mutually impact the matters herein
described, including but not limited to its ability to raise financing on
acceptable terms, successful completion of clinical development programs,
regulatory review and approval, product development and acceptance,
manufacturing, competition, and/or other factors, some of which are outside the
control of the Company.

                                       ##